I would read it that way. Why would you expand the study when so close to unblinding the P3 study unless you were observing some compelling improvements and wanted to be able to rapidly expand the target group.
Imagine if they could give Trofinetide when they begin to deteriorate not afterwards, they may be able to avoid much of the disability.That would be a wonderful outcome!
- Forums
- ASX - By Stock
- NEU
- Ann: Trofinetide Rett syndrome clinical trial in girls aged 2-5
Ann: Trofinetide Rett syndrome clinical trial in girls aged 2-5, page-10
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$13.33 |
Change
-0.480(3.48%) |
Mkt cap ! $1.703B |
Open | High | Low | Value | Volume |
$13.82 | $13.91 | $13.32 | $4.989M | 369.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 500 | $13.32 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.41 | 1680 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 13.320 |
4 | 8758 | 13.300 |
1 | 2114 | 13.290 |
2 | 1885 | 13.280 |
1 | 2114 | 13.270 |
Price($) | Vol. | No. |
---|---|---|
13.410 | 1680 | 2 |
13.440 | 2114 | 1 |
13.450 | 215 | 1 |
13.470 | 2114 | 1 |
13.490 | 2114 | 1 |
Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |